A coming of age for personalised medicine?
This article was originally published in Clinica
The recent agreement between UK diagnostics company Enigma Diagnostics and GlaxoSmithKline to commercialise a rapid point-of-care test for different strains of influenza is the latest in a series of deals that underline the growing importance of so-called companion diagnostics. It is now widely expected that this category of diagnostics will have a big influence on healthcare and the future shape of the pharma and diagnostics markets.
You may also be interested in...
The proceeds from the investment will enable Nyxoah to prepare for the IDE pivotal trial of the Genio system in the US, and accelerate market access and commercialization activities in Europe, Australia and New Zealand.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you would like to see in the format of the content or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Zimmer Biomet reported Q4 results that reflected solid progress in the company’s turnaround efforts, with knees leading the charge. But the company is making slower-than-expected progress resolving FDA warning letter issues and faces a new bribery lawsuit in Mexico.